IMPT-514’s dual CAR approach is designed to ablate B-cells and pathogenic CD20+ T cells for potential therapeutic benefit in MS LOS ANGELES, May 21, 2024 /PRNewswire/ — ImmPACT Bio USA Inc. (ImmPACT Bio), a clinical-stage biopharmaceutical company developing a new generation of cellular…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.